利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.019 秒)

    METHODS AND COMPOSITIONS COMPRISING TAU OLIGOMERS
    1.
    发明申请
    METHODS AND COMPOSITIONS COMPRISING TAU OLIGOMERS 有权

    公开(公告)号：US20210395319A1

    公开(公告)日：2021-12-23

    申请号：US17461862

    申请日：2021-08-30

    申请人： OLIGOMERIX, INC.

    发明人： James G. Moe ,  Eliot J. Davidowitz

    IPC分类号： C07K14/47 ,  C12N9/64 ,  A61K38/17

    摘要： Tau protein has a causative role in Alzheimer's disease and multiple other neurodegenerative disorders exhibiting tau histopathology collectively termed tauopathies. The primary function of tau protein is to facilitate assembly and maintenance of microtubules in neuronal axons. In the disease process tau protein becomes modified, loses its affinity to microtubules and accumulates in the cell body where it forms aggregates. The large neurofibrillary tangles formed from tau protein assembled into filaments were thought to be the pathological structure of tau. However, more recent work indicates that smaller, soluble oligomeric forms of tau are best associated with neuron loss and memory impairment. Here, novel compositions of tau oligomers and novel mechanisms for tau oligomer nucleation, extension and termination are taught. Methods for producing and purifying these structures for the development of small molecule and immunotherapeutics as well as antibodies for biomarkers of neurodegenerative diseases are taught.

    Biomarkers and assays for Alzheimer's disease
    3.
    发明申请
    Biomarkers and assays for Alzheimer's disease 审中-公开
    阿尔茨海默病的生物标记物和测定法

    公开(公告)号：US20080220449A1

    公开(公告)日：2008-09-11

    申请号：US12069399

    申请日：2008-02-08

    申请人： Sara Vasan ,  Eliot J. Davidowitz ,  James G. Moe

    发明人： Sara Vasan ,  Eliot J. Davidowitz ,  James G. Moe

    IPC分类号： G01N33/53 ,  G01N33/00 ,  C07K16/18 ,  G01N33/566

    CPC分类号： C07K16/18 ,  G01N33/6896 ,  G01N2800/2821 ,  G01N2800/56

    摘要： Methods, compositions and systems are provided for diagnosing, stratifying, or monitoring the progression or regression of Alzheimer's disease (AD), the methods, compositions and systems comprise detecting in a sample a level of at least one AD biomarker, the AD biomarker comprising at least phosphorylated tau pT217, soluble tau oligomer, tau-amyloid-beta 1-42 complex, a fragment thereof or a combination thereof and comparing the level from the sample to a reference level of phosphorylated tau pT217, soluble tau oligomer, and/or tau-amyloid-beta 1-42 complex to diagnose or stratify or monitor the progression or regression of AD. In various embodiments, diagnostic assay and screening kits are provided. In various embodiments, the assay and kits provided can monitor the therapeutic effect of a drug and/or AD treatment. In various embodiments, the assay can be used to screen for drugs that disrupt the AD biomarker(s)

    摘要翻译： 提供了用于诊断，分层或监测阿尔茨海默病（AD）的进展或消退的方法，组合物和系统，所述方法，组合物和系统包括在样品中检测至少一种AD生物标志物的水平，所述AD生物标志物包含 最小磷酸化tau pT217，可溶性tau低聚物，tau-淀粉样蛋白-β1-42复合物，其片段或其组合，并将来自样品的水平与磷酸化tau pT217，可溶性tau低聚物和/或tau的参考水平进行比较 - 淀粉样蛋白-β1-42复合物来诊断或分层或监测AD的进展或消退。 在各种实施方案中，提供诊断测定和筛选试剂盒。 在各种实施方案中，提供的测定和试剂盒可以监测药物和/或AD治疗的治疗效果。 在各种实施方案中，该测定可用于筛选破坏AD生物标志物的药物，

    Compositions and methods for binding agglomeration proteins
    4.
    发明授权
    Compositions and methods for binding agglomeration proteins 失效
    用于结合聚集蛋白的组合物和方法

    公开(公告)号：US07232807B2

    公开(公告)日：2007-06-19

    申请号：US11112953

    申请日：2005-04-22

    申请人： Abraham Grossman ,  Valentine M. Kryukov ,  Brian Neil Zeiler

    发明人： Abraham Grossman ,  Valentine M. Kryukov ,  Brian Neil Zeiler

    IPC分类号： C07H21/02 ,  C07H21/00 ,  A61K31/70 ,  C12N15/11

    CPC分类号： C07H21/04 ,  C12Q1/6834 ,  C12Q1/702 ,  G01N33/6803 ,  Y10S977/704 ,  C12Q2565/113 ,  C12Q2525/161 ,  C12Q2525/101

    摘要： Amplibody compositions and methods used to interact with agglomeration proteins are disclosed herein. Compositions herein comprise one or more DNA or RNA molecules having affinity for at least one agglomeration protein. The nucleic acid component is a naturally or non-naturally occuring molecule with twenty or more ribonucleotide bases. For RNA, at least one nucleotide sequence portion of this RNA molecule has affinity to at least one consensus sequence present in the agglomeration RNA-binding protein. The portion of nucleotide sequence of RNA having affinity for agglomeration proteins is a sequence that is derived from either and RNA virus, and RNA agglomeration proteins is a sequence that is derived from either and RNA virus, an RNA phage, a messenger RNA (“mRNA”), a ribosomal RNA (“rRNA), a transfer RNA (“tRNA”), a sequence that is received as a template by one or more RNA dependent RNA polymerases, or a combination thereof. Methods disclosed herein are directed towards detecting the presence of one or more agglomeration proteins in a sample matrix using the amplibody compositions described herein.

    摘要翻译： 本文公开了用于与附聚蛋白相互作用的放大抗体组合物和方法。 本文的组合物包含对至少一种附聚蛋白具有亲和力的一种或多种DNA或RNA分子。 核酸组分是具有二十个以上核糖核苷酸碱基的天然或非天然存在的分子。 对于RNA，该RNA分子的至少一个核苷酸序列部分对结合RNA结合蛋白中存在的至少一个共有序列具有亲和力。 对聚集蛋白具有亲和性的RNA的核苷酸序列部分是衍生自RNA病毒和RNA病毒的序列，RNA附聚蛋白是衍生自RNA病毒，RNA噬菌体，信使RNA（“mRNA”）的序列 “），核糖体RNA（”rRNA“），转移RNA（”tRNA“），通过一种或多种RNA依赖性RNA聚合酶作为模板接受的序列或其组合。本文公开的方法旨在检测 使用本文所述的扩增体组合物在样品基质中存在一种或多种附聚蛋白。

    Methods and compositions comprising tau oligomers
    6.
    发明授权
    Methods and compositions comprising tau oligomers 有权

    公开(公告)号：US11104710B2

    公开(公告)日：2021-08-31

    申请号：US15285181

    申请日：2016-10-04

    申请人： OLIGOMERIX, INC.

    发明人： James G. Moe ,  Eliot J. Davidowitz

    IPC分类号： C07K14/47 ,  A61K38/17 ,  C12N9/64 ,  G01N33/68

    摘要： Tau protein has a causative role in Alzheimer's disease and multiple other neurodegenerative disorders exhibiting tau histopathology collectively termed tauopathies. The primary function of tau protein is to facilitate assembly and maintenance of microtubules in neuronal axons. In the disease process tau protein becomes modified, loses its affinity to microtubules and accumulates in the cell body where it forms aggregates. The large neurofibrillary tangles formed from tau protein assembled into filaments were thought to be the pathological structure of tau. However, more recent work indicates that smaller, soluble oligomeric forms of tau are best associated with neuron loss and memory impairment. Here, novel compositions of tau oligomers and novel mechanisms for tau oligomer nucleation, extension and termination are taught. Methods for producing and purifying these structures for the development of small molecule and immunotherapeutics as well as antibodies for biomarkers of neurodegenerative diseases are taught.

    METHODS AND COMPOSITIONS COMPRISING TAU OLIGOMERS
    7.
    发明申请
    METHODS AND COMPOSITIONS COMPRISING TAU OLIGOMERS 有权
    包含TAU OLIGOMERS的方法和组合物

    公开(公告)号：US20120029169A1

    公开(公告)日：2012-02-02

    申请号：US13060143

    申请日：2009-08-21

    申请人： James G. Moe ,  Eliot J. Davidowitz

    发明人： James G. Moe ,  Eliot J. Davidowitz

    IPC分类号： C07K14/435

    CPC分类号： C07K14/47 ,  A61K38/1709 ,  G01N2500/00 ,  G01N2800/2821

    摘要： Tau protein has a causative role in Alzheimer's disease and multiple other neurodegenerative disorders exhibiting tau histopathology collectively termed tauopathies. The primary function of tau protein is to facilitate assembly and maintenance of microtubules in neuronal axons. In the disease process tau protein becomes modified, loses its affinity to microtubules and accumulates in the cell body where it forms aggregates. The large neurofibrillary tangles formed from tau protein assembled into filaments were thought to be the pathological structure of tau. However, more recent work indicates that smaller, soluble oligomeric forms of tau are best associated with neuron loss and memory impairment. Here, novel compositions of tau oligomers and novel mechanisms for tau oligomer nucleation, extension and termination are taught. Methods for producing and purifying these structures for the development of small molecule and immunotherapeutics as well as antibodies for biomarkers of neurodegenerative diseases are taught.

    摘要翻译： Tau蛋白在阿尔茨海默病和多种其他神经退行性疾病中起着重要的作用，其表现为组织病理学统称为tau蛋白病。 tau蛋白的主要功能是促进神经元轴突中微管的组装和维持。 在疾病过程中，tau蛋白被修饰，丧失其对微管的亲和力，并在细胞体积聚，形成聚集体。 由tau蛋白形成的大的神经原纤维缠结组织成长丝被认为是tau的病理结构。 然而，最近的工作表明，较小的可溶性寡聚体形式的tau最好与神经元损失和记忆障碍有关。 在这里，教导了tau寡聚体的新型组合物和用于tau低聚物成核，延伸和终止的新机制。 制备和纯化用于开发小分子和免疫治疗剂的这些结构的方法以及用于神经变性疾病的生物标志物的抗体。